Drugs / Icosabutate
last change Feb 2025 re-read 2 minutes ago

Icosabutate

also known as PRC-4016 · Icosabutato · NST-4016 · PRB-01022

Small molecule targets FFAR1, FFAR4 via activation

Developed for
hyperlipidemia · metabolic dysfunction-associated steatohepatitis
Investigated by
Pronova BioPharma · NorthSea Therapeutics B.V.

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT03577275 Jun → Sep 2018 hyperlipidemia NorthSea Therapeutics B.V. Completed No outcome recorded
Phase 1 NCT02364635 Feb → Aug 2015 Pronova BioPharma Completed No outcome recorded
Phase 1 NCT02367937 Aug → Oct 2014 Pronova BioPharma Completed No outcome recorded
Phase 1 NCT02373176 Jul → Sep 2014 Pronova BioPharma Completed No outcome recorded
Phase 23 trials
Phase 2 NCT04052516 Jul 2019 → Feb 2022 metabolic dysfunction-associated steatohepatitis NorthSea Therapeutics B.V. Completed No outcome recorded
Phase 2 NCT01972178 Nov 2013 → Jul 2014 hyperlipidemia Pronova BioPharma Terminated No outcome recorded
Phase 2 NCT01893515 Jul 2013 → Jul 2014 hyperlipidemia Pronova BioPharma Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as icosabutate ClinicalTrials.gov intervention name — accepted as the source's own label NCT02367937
3

NCT02364635

NCT02373176

NCT04052516

Known as Icosabutato ChEMBL registry synonym — accepted as the source's own label CHEMBL3707220
Known as NST-4016 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03577275
Known as PRB-01022 PRB-01022 (icosabutate) (unchanged drug)” NCT02373176
Known as PRC-4016 “[14C]PRC-4016 (Icosabutate)” NCT02373176
3

PRC-4016 (icosabutate)” NCT02367937

NCT01972178

NCT01893515

Action Activate “icosabutate, a FFAR1/FFAR4 agonist” PMID 39938653 Feb 2025
Modality Small molecule CHEMBL3707220
Route Oral “PRC-4016, oral administration once daily, capsule” NCT01893515
Target FFAR1 “icosabutate, a FFAR1/FFAR4 agonist” PMID 39938653 Feb 2025
Target FFAR4 “icosabutate, a FFAR1/FFAR4 agonist” PMID 39938653 Feb 2025